GBR 830

Drug Profile

GBR 830

Alternative Names: GBR830

Latest Information Update: 16 May 2016

Price : $50

At a glance

  • Originator Glenmark Pharmaceuticals S.A.
  • Class Monoclonal antibodies
  • Mechanism of Action OX40 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis
  • Phase I Autoimmune disorders
  • Preclinical Inflammatory bowel diseases; Rheumatoid arthritis

Most Recent Events

  • 01 Mar 2016 Phase-II clinical trials in Atopic dermatitis in Canada, USA (IV) (NCT02683928)
  • 12 Feb 2016 Glenmark Pharmaceuticals plans a phase IIa trial in Atopic dermatitis in USA and Canada (NCT02683928)
  • 03 Sep 2015 Glenmark plans a phase II trial in Coeliac disease in USA and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top